Findings of Research Misconduct, 54701-54703 [2022-19263]
Download as PDF
<![CDATA[
lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 87, No. 172 / Wednesday, September 7, 2022 / Notices
membership requirements are set forth
in section 2119 of the National
Childhood Vaccine Injury Act.
The ACCV consists of nine voting
members appointed by the Secretary as
follows: (1) Three health professionals,
who are not employees of the U.S.
government, and who have expertise in
the health care of children, the
epidemiology, etiology, and prevention
of childhood diseases, and the adverse
reactions associated with vaccines, of
whom at least two shall be
pediatricians; (2) three members from
the general public, of whom at least two
shall be legal representatives (parents or
guardians) of children who have
suffered a vaccine-related injury or
death; and (3) three attorneys, of whom
at least one shall be an attorney whose
specialty includes representation of
persons who have suffered a vaccinerelated injury or death, and of whom
one shall be an attorney whose specialty
includes representation of vaccine
manufacturers. In addition, the Director
of the National Institutes of Health, the
Assistant Secretary for Health, the
Director of the Centers for Disease
Control and Prevention, and the
Commissioner of the Food and Drug
Administration (or the designees of such
officials) serve as non-voting ex officio
members.
HHS will consider nominations of all
qualified individuals with a view to
ensure that the ACCV includes the areas
of subject matter expertise noted above.
As indicated above, at least two of the
three ACCV members of the general
public must be legal representatives
(parents or guardians) of children who
have suffered a vaccine-related injury or
death. Because those members must be
the legal representatives of children
who have suffered a vaccine-related
injury or death, to be considered for
appointment to the ACCV in that
category, there must have been a finding
(i.e., a decision) by the U.S. Court of
Federal Claims or a civil court that a
VICP-covered vaccine caused, or was
presumed to have caused, the
represented child’s injury or death.
Additionally, based on a
recommendation made by the ACCV,
the Secretary will consider having a
health professional with expertise in
obstetrics as one of the members of the
general public. Interested applicants
may self-nominate or be nominated by
another individual or organization.
Individuals selected for appointment
to the Committee will be invited to
serve for up to 3 years. Members are
appointed as SGEs and receive a stipend
and reimbursement for per diem and
travel expenses incurred for attending
ACCV meetings and/or conducting other
VerDate Sep<11>2014
17:50 Sep 06, 2022
Jkt 256001
business on behalf of the ACCV, as
authorized by 5 U.S.C. 5703 for persons
employed intermittently in government
service.
The following information must be
included in the package of materials
submitted for each individual
nominated for consideration: (1) a letter
of nomination stating the name,
affiliation, and contact information for
the nominee, the basis for the
nomination (i.e., what specific
attributes, perspectives, and/or skills
does the individual possess that would
benefit the workings of the ACCV) and
the nominee’s field(s) of expertise; (2)
the name, address, daytime telephone
number, and email address at which the
nominator can be contacted; and (3) a
current copy of the nominee’s
curriculum vitae. The individual being
nominated or the person/organization
recommending the candidate may
submit nomination packages directly to
HRSA, which will collect and retain
nomination packages to create a pool of
possible future ACCV voting members.
When a vacancy occurs, HRSA and HHS
will review nomination packages from
the appropriate category and nominees
may be contacted at that time.
HHS endeavors to ensure that the
membership of the ACCV is fairly
balanced in terms of points of view
represented and that individuals from a
broad representation of geographic
areas, gender, and ethnic and minority
groups, as well as individuals with
disabilities, are considered for
membership. Appointments shall be
made without discrimination on the
basis of race, age, ethnicity, national
origin, gender, disability, sexual
orientation, or cultural, religious, or
socioeconomic status.
Individuals who are selected to be
considered for appointment will be
required to provide detailed information
regarding their financial holdings,
consultancies, and research grants or
contracts. Disclosure of this information
is required for HRSA ethics officials to
determine whether there is a potential
conflict of interest between the SGE’s
public duties as a member of the ACCV
and their private interests, including an
appearance of a loss of impartiality as
defined by federal laws and regulations,
and to identify any required remedial
action needed to address the potential
conflict.
Authority: Under the authorities that
established the ACCV, the Federal
Advisory Committee Act of October 6,
1972, (Pub. L. 92–463) and section 2119
of the National Childhood Vaccine
Injury Act (Pub. L. 99–660, as
amended), HRSA is requesting
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
54701
nominations for voting members of the
ACCV.
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2022–19242 Filed 9–6–22; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
Findings of research
misconduct have been made against
Ritankar Majumdar, Ph.D. (Respondent),
who was a postdoctoral fellow in the
intramural program of the Laboratory of
Cellular and Molecular Biology (CMB),
Center for Cancer Research (CCR),
National Cancer Institute (NCI),
National Institutes of Health (NIH).
Respondent engaged in research
misconduct in research supported by
U.S. Public Health Service (PHS) funds,
specifically the NCI Intramural Research
Program. The administrative actions,
including supervision for a period of
three (3) years, were implemented
beginning on August 15, 2022, and are
detailed below.
FOR FURTHER INFORMATION CONTACT:
Wanda K. Jones, Dr.P.H., Acting
Director, Office of Research Integrity,
1101 Wootton Parkway, Suite 240,
Rockville, MD 20852, (240) 453–8200.
SUPPLEMENTARY INFORMATION: Notice is
hereby given that the Office of Research
Integrity (ORI) has taken final action in
the following case:
Ritankar Majumdar, Ph.D., National
Institutes of Health: Based on the report
of an investigation conducted by NIH
and analysis conducted by ORI in its
oversight review, ORI found that Dr.
Ritankar Majumdar, former postdoctoral
fellow in the intramural program of the
Laboratory of CMB, CCR, NCI, NIH,
engaged in research misconduct in
research supported by PHS funds,
specifically the NCI Intramural Research
Program.
ORI found that Respondent engaged
in research misconduct by knowingly or
recklessly falsifying and/or fabricating
data in the following one (1) published
paper, one (1) manuscript, three (3) PHS
grant applications, and fifteen (15)
presentations:
• Exosomes Mediate LTB4 Release
during Neutrophil Chemotaxis. PloS
Biol. 2016 Jan 7; 14(1):e1002336; doi:
10.1371/journal.pbio.1002336 (hereafter
referred to as ‘‘PloS Biol 2016’’).
SUMMARY:
E:\FR\FM\07SEN1.SGM
07SEN1
lotter on DSK11XQN23PROD with NOTICES1
54702
Federal Register / Vol. 87, No. 172 / Wednesday, September 7, 2022 / Notices
Retraction in: PLoS Biol. 2021 Jul
7;19(7):e3001320; doi: 10.1371/
journal.pbio.3001320.
• Biogenesis of Leukotriene B4Containing Exosomes at the Nuclear
Envelope. Manuscript accepted for
publication in Nature Cell Biology in
2019 and withdrawn (hereafter referred
to as the ‘‘NCB manuscript’’).
• R01 AI145072–01, ‘‘Signal relay
during directed cell migration,’’
submitted to the National Institute of
Allergy and Infectious Diseases (NIAID),
NIH, on 06/04/2018.
• R01 AI145072–01A1, ‘‘Signal relay
during directed cell migration,’’
submitted to NIAID, NIH, on 04/16/
2019.
• R01 AI152517–01, ‘‘Signal relay
during directed cell migration,’’
submitted to NIAID, NIH, on 08/16/
2019, funded from 07/10/2020–6/30/
2025.
• LTB4-synthesizing enzymes
aggregate on nuclear lipid rafts that bud
exosomes to mediate signal relay during
neutrophil chemotaxis. Poster
Presentation at the University of
Maryland (UMD) in 2016 (hereafter
referred to as the ‘‘UMD 2016
presentation’’).
• Exosome secretion as an effective
mechanism of LTB4-mediated signal
relay in migrating neutrophils. Oral
presentation at the American Society for
Exosomes and Microvesicles (ASEM) on
10/17/2015 (hereafter referred to as the
‘‘ASEM 2015 presentation’’).
• Chemotactic gradient amplification
through the release of extracellular
vesicles during eukaryotic chemotaxis.
Oral presentation at Collective
Dynamics in Microorganisms and
Cellular Systems (CDMCS) on 05/25/
2016 (hereafter referred to as the
‘‘CDMCS 2016 presentation’’).
• Signal Relay is Mediated by
Exosome Release during Dictyostelium
and Neutrophil Chemotaxis. Oral
presentation at International CIM (Cells
in Motion) Symposium 2015 on 09/14/
2015 (hereafter referred to as the ‘‘CIM
2015 presentation’’).
• Do ESCRTS DR(ea)M of nuclear
MVBs? Interplay of ESCRT Dependent
and Independent processes in Exosome
Biogenesis during Relay of Chemotactic
Signals in Neutrophils. Poster
presentation at Directed Cell Migration
Gordon Research Conference (GRC)
from 01/22/2017–01/27/2017 (hereafter
referred to as the ‘‘GRC 2017
presentation’’).
• Nuclear Lipid Microdomains as a
Novel Niche for Exosome Biogenesis:
Interplay of ESCRT Dependent and
Independent Processes During Relay of
Chemotactic Signals in Neutrophils OR
Do ESCRTs DR(ea)M of nuclear MVBs?
VerDate Sep<11>2014
17:50 Sep 06, 2022
Jkt 256001
Oral presentation at Directed Cell
Migration Gordon Research Seminar
(GRS) on 01/21/2017 (GRS2017.pptx)
(hereafter referred to as the ‘‘GRS 2017
presentation’’).
• Lab Meeting on 02/13/15 (hereafter
referred to as ‘‘Lab Meeting 02/13/15’’).
• Lab Meeting in August 2015
(hereafter referred to as ‘‘Lab Meeting
08/2015’’).
• Lab Meeting on October 7, 2016
(hereafter referred to as ‘‘Lab Meeting
10/07/2016’’).
• Lab Meeting in July 2016 (hereafter
referred to as ‘‘Lab Meeting 07/2016’’).
• A series of fortunate events. Lab
Meeting in December 2016 (hereafter
referred to as ‘‘Lab Meeting 12/2016’’).
• Lab Meeting on November 4, 2015
(hereafter referred to as ‘‘Lab Meeting
11/04/2015’’).
• Exosome secretion as an effective
mechanism of LTB4 mediated signal
relay in migrating neutrophils. LCMB
Presentation in 2015 (hereafter referred
to as ‘‘LCMB 2015 presentation V1’’).
• Exosome secretion as an effective
mechanism of LTB4 mediated signal
relay in migrating neutrophils. LCMB
Presentation in 2015 (hereafter referred
to as ‘‘LCMB 2015 presentation V2’’).
• Extracellular Vesicles mediate
signal relay during Chemotaxis. LCMB
Seminar in 2014 (hereafter referred to as
‘‘LCMB 2014 seminar’’).
• Data compilation for LCMB
Seminar in 2016 (hereafter referred to as
‘‘LCMB 2016 seminar data 1’’).
• A series of fortunate events: Do
ESCRTs DR(ea)M of nuclear MVBs? Oral
presentation at LCMB in 2016 (hereafter
referred to as ‘‘LCMB 2016 seminar data
2’’).
Specifically, ORI found that:
• Respondent knowingly or recklessly
falsified and/or fabricated electron
microscopic (EM) image data for the
formation of multivesicular bodies
(MVBs) in migrating primary
neutrophils following chemoattractant
activation by:
—adding and/or removing 5lipoxygenase (5–LO) immunogold
signal and/or cell organelle
membranes and/or subcellular
vesicles in:
➢ NCB manuscript:
—Figure 1B, also included in:
D Figure 4C in R01 AI145072–01
D Figure 3B in R01 AI145072–01A1
D Slide 8 in Lab Meeting 10/07/2016
D Slide 2 in Lab Meeting 12/2016
D Column 2, Row 1 in GRC 2017
presentation 1
—Figures 1C and 1D
—Figure 7D, also included in:
D Slide 14 in Lab Meeting 10/07/2016
D Slide 3 in Lab Meeting 12/2016
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
D Column 2 Row 4 in GRC 2017
presentation 1
➢ PloS Biology 2016:
—Figure 2A, also included in:
D Figure 11 in UMD 2016 presentation
—Figure 2B, also included in:
D Slide 20 in LCMB 2015 presentation
V1
D Slide 20 in LCMB 2015 presentation
V2
—Figure 2C, also included in:
D Slide 20 in LCMB 2015 presentation
V1
D Slide 22 in LCMB 2015 presentation
V2
D Slide 6 in GRS 2017 presentation 2
—Figure 2Giii, also included in:
D Figure 3 in R01 AI145072–01
D Figure 2 in R01 AI145072–01A1
D Figure 2 in R01 AI152517–01
D Slide 20 in Lab Meeting 08/2015
D Slide 5 in Lab Meeting 07/2016
D Slide 17 in Lab Meeting 11/04/2015
D Slide 18 in LCMB 2015 presentation
V1
D Slide 68 in LCMB 2015 presentation
V2
D Slides 7 and 13 in LCMB 2016
seminar data 1
D Slides 6 and 12 in LCMB 2016
seminar data 2
D Figure 1b in UMD 2016
presentation
D Slide 16 in ASEM 2015 presentation
D Slide 32 in CDMCS 2016
presentation
D Slide 46 in CIM 2015 presentation
D Column 1, Row 4 in GRC 2017
presentation 1
D Slides 10 and 12 in GRS 2017
presentation 2
➢ R01 AI145072–01A1:
—Figure 3D, also included in:
D Figure 3D in R01 AI152517–01
D Figure 4Diii in AI145072–01
D Slide 4 in Lab Meeting 12/2016
—presenting EM images from the same
source and falsely relabeling them to
represent different experimental
results in:
➢ Figures 1A and 7D in the NCB
manuscript
➢ Figures 2A and 2D in PloS Biology
2016
• Respondent knowingly or recklessly
falsified and/or fabricated immunoblot
image data for chemoattractant
activation of MVBs in migrating primary
neutrophils in:
—Supplemental Figure 2B of the NCB
manuscript:
➢ by copying the panel representing
‘‘5–LO’’ in Figure 1C in PloS
Biology 2016, and flipping, resizing, and relabeling it to represent
‘‘Flotillin’’
➢ by copying the panel representing
E:\FR\FM\07SEN1.SGM
07SEN1
lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 87, No. 172 / Wednesday, September 7, 2022 / Notices
‘‘5–LO’’ in the second row of the
left column in Slide 9 in Lab
Meeting 02/13/15 and rotating,
resizing, and relabeling to represent
‘‘Laminin’’
• Respondent knowingly or recklessly
falsified and/or fabricated time-lapse
confocal microscopic image data for
nuclear envelope vesicle formation by
falsely presenting still images in reverse
order from the original movies in the
NCB manuscript:
—Supplemental Movie S1
—Figure 2A, also included in:
➢ Figure 4 in R01 AI145072–01A1
➢ Slide 8 in Lab Meeting 07/2016
➢ Figure 11 in UMD 2016
presentation
➢ Slide 38 in LCMB 2016 seminar
data 1
Dr. Majumdar entered into a
Voluntary Settlement Agreement
(Agreement) and voluntarily agreed to
the following:
(1) Respondent will have his research
supervised for a period of three (3) years
beginning on August 15, 2022 (the
‘‘Supervision Period’’). Prior to the
submission of an application for PHS
support for a research project on which
Respondent’s participation is proposed
and prior to Respondent’s participation
in any capacity in PHS-supported
research, Respondent will submit a plan
for supervision of Respondent’s duties
to ORI for approval. The supervision
plan must be designed to ensure the
integrity of Respondent’s research.
Respondent will not participate in any
PHS-supported research until such a
supervision plan is approved by ORI.
Respondent will comply with the
agreed-upon supervision plan.
(2) The requirements for Respondent’s
supervision plan are as follows:
i. A committee of 2–3 senior faculty
members at the institution who are
familiar with Respondent’s field of
research, but not including
Respondent’s supervisor or
collaborators, will provide oversight and
guidance for a period of three (3) years
from the effective date of the
Agreement. The committee will review
primary data from Respondent’s
laboratory on a quarterly basis and
submit a report to ORI at six (6) month
intervals setting forth the committee
meeting dates and Respondent’s
compliance with appropriate research
standards and confirming the integrity
of Respondent’s research.
ii. The committee will conduct an
advance review of each application for
PHS funds, or report, manuscript, or
abstract involving PHS-supported
research in which Respondent is
involved. The review will include a
VerDate Sep<11>2014
17:50 Sep 06, 2022
Jkt 256001
discussion with Respondent of the
primary data represented in those
documents and will include a
certification to ORI that the data
presented in the proposed application,
report, manuscript, or abstract are
supported by the research record.
(3) During the Supervision Period,
Respondent will ensure that any
institution employing him submits, in
conjunction with each application for
PHS funds, or report, manuscript, or
abstract involving PHS-supported
research in which Respondent is
involved, a certification to ORI that the
data provided by Respondent are based
on actual experiments or are otherwise
legitimately derived and that the data,
procedures, and methodology are
accurately reported and not plagiarized
in the application, report, manuscript,
or abstract.
(4) If no supervision plan is provided
to ORI, Respondent will provide
certification to ORI at the conclusion of
the Supervision Period that his
participation was not proposed on a
research project for which an
application for PHS support was
submitted and that he has not
participated in any capacity in PHSsupported research.
(5) During the Supervision Period,
Respondent will exclude himself
voluntarily from serving in any advisory
or consultant capacity to PHS including,
but not limited to, service on any PHS
advisory committee, board, and/or peer
review committee.
Dated: September 1, 2022.
Wanda K. Jones,
Acting Director, Office of Research Integrity,
Office of the Assistant Secretary for Health.
[FR Doc. 2022–19263 Filed 9–6–22; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
contract proposals and the discussions
could disclose confidential trade secrets
or commercial property such as
patentable material, and personal
information concerning individuals
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
54703
associated with the grant applications
and contract proposals, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Cancer
Epidemiology Cohort Studies.
Date: October 13, 2022.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W254, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Susan Lynn Spence, Ph.D.,
Scientific Review Officer, Research
Technology and Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W254, Rockville, Maryland
20850, 240–620–0819, susan.spence@
nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel;
Technologies for Global Health.
Date: October 14, 2022.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W608, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Nadeem Khan, Ph.D.,
Scientific Review Officer, Research
Technology and Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W608, Rockville, Maryland
20850, 240–276–5856, nadeem.khan@
nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–4: NCI
Clinical and Translational Cancer Research.
Date: October 18, 2022.
Time: 9:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W640, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Saejeong J. Kim, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W640 Rockville,
Maryland 20850, 240–276–7684,
saejeong.kim@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel;
Therapeutics for Pediatric and Rare Cancers.
Date: October 20, 2022.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W608, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Nadeem Khan, Ph.D.,
Scientific Review Officer, Research
Technology and Contract Review Branch,
E:\FR\FM\07SEN1.SGM
07SEN1
]]>Agencies
[Federal Register Volume 87, Number 172 (Wednesday, September 7, 2022)]
[Notices]
[Pages 54701-54703]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-19263]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Findings of research misconduct have been made against
Ritankar Majumdar, Ph.D. (Respondent), who was a postdoctoral fellow in
the intramural program of the Laboratory of Cellular and Molecular
Biology (CMB), Center for Cancer Research (CCR), National Cancer
Institute (NCI), National Institutes of Health (NIH). Respondent
engaged in research misconduct in research supported by U.S. Public
Health Service (PHS) funds, specifically the NCI Intramural Research
Program. The administrative actions, including supervision for a period
of three (3) years, were implemented beginning on August 15, 2022, and
are detailed below.
FOR FURTHER INFORMATION CONTACT: Wanda K. Jones, Dr.P.H., Acting
Director, Office of Research Integrity, 1101 Wootton Parkway, Suite
240, Rockville, MD 20852, (240) 453-8200.
SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of
Research Integrity (ORI) has taken final action in the following case:
Ritankar Majumdar, Ph.D., National Institutes of Health: Based on
the report of an investigation conducted by NIH and analysis conducted
by ORI in its oversight review, ORI found that Dr. Ritankar Majumdar,
former postdoctoral fellow in the intramural program of the Laboratory
of CMB, CCR, NCI, NIH, engaged in research misconduct in research
supported by PHS funds, specifically the NCI Intramural Research
Program.
ORI found that Respondent engaged in research misconduct by
knowingly or recklessly falsifying and/or fabricating data in the
following one (1) published paper, one (1) manuscript, three (3) PHS
grant applications, and fifteen (15) presentations:
Exosomes Mediate LTB4 Release during Neutrophil
Chemotaxis. PloS Biol. 2016 Jan 7; 14(1):e1002336; doi: 10.1371/
journal.pbio.1002336 (hereafter referred to as ``PloS Biol 2016'').
[[Page 54702]]
Retraction in: PLoS Biol. 2021 Jul 7;19(7):e3001320; doi: 10.1371/
journal.pbio.3001320.
Biogenesis of Leukotriene B4-Containing Exosomes at the
Nuclear Envelope. Manuscript accepted for publication in Nature Cell
Biology in 2019 and withdrawn (hereafter referred to as the ``NCB
manuscript'').
R01 AI145072-01, ``Signal relay during directed cell
migration,'' submitted to the National Institute of Allergy and
Infectious Diseases (NIAID), NIH, on 06/04/2018.
R01 AI145072-01A1, ``Signal relay during directed cell
migration,'' submitted to NIAID, NIH, on 04/16/2019.
R01 AI152517-01, ``Signal relay during directed cell
migration,'' submitted to NIAID, NIH, on 08/16/2019, funded from 07/10/
2020-6/30/2025.
LTB4-synthesizing enzymes aggregate on nuclear lipid rafts
that bud exosomes to mediate signal relay during neutrophil chemotaxis.
Poster Presentation at the University of Maryland (UMD) in 2016
(hereafter referred to as the ``UMD 2016 presentation'').
Exosome secretion as an effective mechanism of LTB4-
mediated signal relay in migrating neutrophils. Oral presentation at
the American Society for Exosomes and Microvesicles (ASEM) on 10/17/
2015 (hereafter referred to as the ``ASEM 2015 presentation'').
Chemotactic gradient amplification through the release of
extracellular vesicles during eukaryotic chemotaxis. Oral presentation
at Collective Dynamics in Microorganisms and Cellular Systems (CDMCS)
on 05/25/2016 (hereafter referred to as the ``CDMCS 2016
presentation'').
Signal Relay is Mediated by Exosome Release during
Dictyostelium and Neutrophil Chemotaxis. Oral presentation at
International CIM (Cells in Motion) Symposium 2015 on 09/14/2015
(hereafter referred to as the ``CIM 2015 presentation'').
Do ESCRTS DR(ea)M of nuclear MVBs? Interplay of ESCRT
Dependent and Independent processes in Exosome Biogenesis during Relay
of Chemotactic Signals in Neutrophils. Poster presentation at Directed
Cell Migration Gordon Research Conference (GRC) from 01/22/2017-01/27/
2017 (hereafter referred to as the ``GRC 2017 presentation'').
Nuclear Lipid Microdomains as a Novel Niche for Exosome
Biogenesis: Interplay of ESCRT Dependent and Independent Processes
During Relay of Chemotactic Signals in Neutrophils OR Do ESCRTs DR(ea)M
of nuclear MVBs? Oral presentation at Directed Cell Migration Gordon
Research Seminar (GRS) on 01/21/2017 (GRS2017.pptx) (hereafter referred
to as the ``GRS 2017 presentation'').
Lab Meeting on 02/13/15 (hereafter referred to as ``Lab
Meeting 02/13/15'').
Lab Meeting in August 2015 (hereafter referred to as ``Lab
Meeting 08/2015'').
Lab Meeting on October 7, 2016 (hereafter referred to as
``Lab Meeting 10/07/2016'').
Lab Meeting in July 2016 (hereafter referred to as ``Lab
Meeting 07/2016'').
A series of fortunate events. Lab Meeting in December 2016
(hereafter referred to as ``Lab Meeting 12/2016'').
Lab Meeting on November 4, 2015 (hereafter referred to as
``Lab Meeting 11/04/2015'').
Exosome secretion as an effective mechanism of LTB4
mediated signal relay in migrating neutrophils. LCMB Presentation in
2015 (hereafter referred to as ``LCMB 2015 presentation V1'').
Exosome secretion as an effective mechanism of LTB4
mediated signal relay in migrating neutrophils. LCMB Presentation in
2015 (hereafter referred to as ``LCMB 2015 presentation V2'').
Extracellular Vesicles mediate signal relay during
Chemotaxis. LCMB Seminar in 2014 (hereafter referred to as ``LCMB 2014
seminar'').
Data compilation for LCMB Seminar in 2016 (hereafter
referred to as ``LCMB 2016 seminar data 1'').
A series of fortunate events: Do ESCRTs DR(ea)M of nuclear
MVBs? Oral presentation at LCMB in 2016 (hereafter referred to as
``LCMB 2016 seminar data 2'').
Specifically, ORI found that:
Respondent knowingly or recklessly falsified and/or
fabricated electron microscopic (EM) image data for the formation of
multivesicular bodies (MVBs) in migrating primary neutrophils following
chemoattractant activation by:
--adding and/or removing 5-lipoxygenase (5-LO) immunogold signal and/or
cell organelle membranes and/or subcellular vesicles in:
[rtarr8] NCB manuscript:
--Figure 1B, also included in:
[ssquf] Figure 4C in R01 AI145072-01
[ssquf] Figure 3B in R01 AI145072-01A1
[ssquf] Slide 8 in Lab Meeting 10/07/2016
[ssquf] Slide 2 in Lab Meeting 12/2016
[ssquf] Column 2, Row 1 in GRC 2017 presentation 1
--Figures 1C and 1D
--Figure 7D, also included in:
[ssquf] Slide 14 in Lab Meeting 10/07/2016
[ssquf] Slide 3 in Lab Meeting 12/2016
[ssquf] Column 2 Row 4 in GRC 2017 presentation 1
[rtarr8] PloS Biology 2016:
--Figure 2A, also included in:
[ssquf] Figure 11 in UMD 2016 presentation
--Figure 2B, also included in:
[ssquf] Slide 20 in LCMB 2015 presentation V1
[ssquf] Slide 20 in LCMB 2015 presentation V2
--Figure 2C, also included in:
[ssquf] Slide 20 in LCMB 2015 presentation V1
[ssquf] Slide 22 in LCMB 2015 presentation V2
[ssquf] Slide 6 in GRS 2017 presentation 2
--Figure 2Giii, also included in:
[ssquf] Figure 3 in R01 AI145072-01
[ssquf] Figure 2 in R01 AI145072-01A1
[ssquf] Figure 2 in R01 AI152517-01
[ssquf] Slide 20 in Lab Meeting 08/2015
[ssquf] Slide 5 in Lab Meeting 07/2016
[ssquf] Slide 17 in Lab Meeting 11/04/2015
[ssquf] Slide 18 in LCMB 2015 presentation V1
[ssquf] Slide 68 in LCMB 2015 presentation V2
[ssquf] Slides 7 and 13 in LCMB 2016 seminar data 1
[ssquf] Slides 6 and 12 in LCMB 2016 seminar data 2
[ssquf] Figure 1b in UMD 2016 presentation
[ssquf] Slide 16 in ASEM 2015 presentation
[ssquf] Slide 32 in CDMCS 2016 presentation
[ssquf] Slide 46 in CIM 2015 presentation
[ssquf] Column 1, Row 4 in GRC 2017 presentation 1
[ssquf] Slides 10 and 12 in GRS 2017 presentation 2
[rtarr8] R01 AI145072-01A1:
--Figure 3D, also included in:
[ssquf] Figure 3D in R01 AI152517-01
[ssquf] Figure 4Diii in AI145072-01
[ssquf] Slide 4 in Lab Meeting 12/2016
--presenting EM images from the same source and falsely relabeling them
to represent different experimental results in:
[rtarr8] Figures 1A and 7D in the NCB manuscript
[rtarr8] Figures 2A and 2D in PloS Biology 2016
Respondent knowingly or recklessly falsified and/or
fabricated immunoblot image data for chemoattractant activation of MVBs
in migrating primary neutrophils in:
--Supplemental Figure 2B of the NCB manuscript:
[rtarr8] by copying the panel representing ``5-LO'' in Figure 1C in
PloS Biology 2016, and flipping, re-sizing, and relabeling it to
represent ``Flotillin''
[rtarr8] by copying the panel representing
[[Page 54703]]
``5-LO'' in the second row of the left column in Slide 9 in Lab Meeting
02/13/15 and rotating, resizing, and relabeling to represent
``Laminin''
Respondent knowingly or recklessly falsified and/or
fabricated time-lapse confocal microscopic image data for nuclear
envelope vesicle formation by falsely presenting still images in
reverse order from the original movies in the NCB manuscript:
--Supplemental Movie S1
--Figure 2A, also included in:
[rtarr8] Figure 4 in R01 AI145072-01A1
[rtarr8] Slide 8 in Lab Meeting 07/2016
[rtarr8] Figure 11 in UMD 2016 presentation
[rtarr8] Slide 38 in LCMB 2016 seminar data 1
Dr. Majumdar entered into a Voluntary Settlement Agreement
(Agreement) and voluntarily agreed to the following:
(1) Respondent will have his research supervised for a period of
three (3) years beginning on August 15, 2022 (the ``Supervision
Period''). Prior to the submission of an application for PHS support
for a research project on which Respondent's participation is proposed
and prior to Respondent's participation in any capacity in PHS-
supported research, Respondent will submit a plan for supervision of
Respondent's duties to ORI for approval. The supervision plan must be
designed to ensure the integrity of Respondent's research. Respondent
will not participate in any PHS-supported research until such a
supervision plan is approved by ORI. Respondent will comply with the
agreed-upon supervision plan.
(2) The requirements for Respondent's supervision plan are as
follows:
i. A committee of 2-3 senior faculty members at the institution who
are familiar with Respondent's field of research, but not including
Respondent's supervisor or collaborators, will provide oversight and
guidance for a period of three (3) years from the effective date of the
Agreement. The committee will review primary data from Respondent's
laboratory on a quarterly basis and submit a report to ORI at six (6)
month intervals setting forth the committee meeting dates and
Respondent's compliance with appropriate research standards and
confirming the integrity of Respondent's research.
ii. The committee will conduct an advance review of each
application for PHS funds, or report, manuscript, or abstract involving
PHS-supported research in which Respondent is involved. The review will
include a discussion with Respondent of the primary data represented in
those documents and will include a certification to ORI that the data
presented in the proposed application, report, manuscript, or abstract
are supported by the research record.
(3) During the Supervision Period, Respondent will ensure that any
institution employing him submits, in conjunction with each application
for PHS funds, or report, manuscript, or abstract involving PHS-
supported research in which Respondent is involved, a certification to
ORI that the data provided by Respondent are based on actual
experiments or are otherwise legitimately derived and that the data,
procedures, and methodology are accurately reported and not plagiarized
in the application, report, manuscript, or abstract.
(4) If no supervision plan is provided to ORI, Respondent will
provide certification to ORI at the conclusion of the Supervision
Period that his participation was not proposed on a research project
for which an application for PHS support was submitted and that he has
not participated in any capacity in PHS-supported research.
(5) During the Supervision Period, Respondent will exclude himself
voluntarily from serving in any advisory or consultant capacity to PHS
including, but not limited to, service on any PHS advisory committee,
board, and/or peer review committee.
Dated: September 1, 2022.
Wanda K. Jones,
Acting Director, Office of Research Integrity, Office of the Assistant
Secretary for Health.
[FR Doc. 2022-19263 Filed 9-6-22; 8:45 am]
BILLING CODE 4150-31-P
